Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) filed its Monthly Return for the period ended 31 July 2026, confirming stable equity capital with no new share issuances, cancellations or treasury share movements during the month.

Authorised and Issued Capital • Authorised/registered share capital remained at 2.67 billion shares, comprising 2.12 billion A-shares and 551.94 million H-shares, each with a par value of RMB 1. • Issued shares also stayed constant at 2.64 billion, split between 2.10 billion A-shares and 540.97 million H-shares. Treasury shares held steady at 19.91 million A-shares and 10.97 million H-shares.

Public Float The company affirmed compliance with the Hong Kong Stock Exchange’s minimum 5% public-float requirement for its H-share class.

Equity Incentive Schemes • 2025 A-Share Option Scheme: 4.45 million options were outstanding; no options were exercised or cancelled in July. The scheme still allows issuance of up to 1.15 million additional A-shares. • 2025 H-Share RSU Scheme: 10.38 million restricted share units remained outstanding, with no H-shares issued or treasury shares transferred during the month.

Other Securities The filing reported no warrants, convertible securities, or other agreements affecting share capital in July 2026. No funds were raised during the period.

The submission was made by Tricor Investor Services Limited, acting as H-share registrar, on 6 August 2026.